Combining Our Strengths
As part of AstraZeneca, we are working to expand access to our portfolio of medicines to improve outcomes for more people living with rare hematological diseases worldwide.
Hematology
Working to improve potential outcomes for more people living with rare hematological diseases worldwide.
Innovating in Hematology
For more than two decades, our innovations in rare disease medicines have positively transformed the trajectory of the patient journey for people living with certain rare hematological diseases-establishing and advancing the treatment landscape for a rare, chronic, progressive and potentially life-threatening blood disease driven by dysregulation of the complement system.
We are committed to following the science, improving the understanding of rare hematological diseases and enhancing the patient and caregiver journey.
Bone Metabolism
Researching and developing innovative treatments that aim to target the underlying causes of rare bone disorders.
Cardiology
Following the science to develop and evaluate potential innovative treatment options to help people living with rare cardiology conditions.
Endocrinology
Identifying potential new opportunities to advance care for those impacted by rare endocrine diseases.
Nephrology
Enhancing the understanding of rare renal diseases and accelerating
the development of potential therapies.
Neurology
Striving to advance scientific understanding in rare neurology and to accelerate the development of potential life-changing treatments.
Rare Cancers
Striving to advance scientific understanding of rare cancers to bring
new solutions.